Jefferies Trims PT on BioMarin Pharma (BMRN), Keeps 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
BMO Capital Starts BioMarin Pharmaceutical Inc. (BMRN) at Outperform
April 6, 2016 4:23 PM EDTBMO Capital initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Outperform rating and a price target of $99.00.
Analyst M. Ian Somaiya commented: "We are initiating coverage on BMRN with an Outperform rating and $99 target price. Our Outperform rating is based on our belief that BioMarin can more than double its revenue base from 2015 to... More
